EVO ICL is an Implantable Collamer Lens (ICL) designed to correct nearsightedness with and without astigmatism.
The small flexible lens is placed behind the iris (the colored part of the eye) and in front of the natural crystalline lens in order to improve vision. It's like having your doctor implant a lens similar to a contact lens into your eye so you can live without the daily hassles and maintenance of typical contact lenses.
EVO ICL lens is made of biocompatible Collamer material that works in harmony with your eye. Your eye doctor will create a small opening in your cornea that will be used to insert and position the EVO ICL. For most patients, the procedure is virtually painless with numbing eye drops and it typically takes less than approximately 5 minutes. Patients typically experience improved vision right away and a quick recovery time.
EVO ICL is now available in Pennsylvania.
The cost of an EVO ICL procedure can vary depending on your personalized treatment plan. Many EVO ICL patients look forward to spending less in the long run with the EVO ICL compared to the continued costs of contacts and glasses. Ask about financing options and payment plans that may be available for your EVO ICL procedure.
EVO ICL is well-suited for a wide variety of people. Ideal candidates for EVO ICL are aged 21 to 45 with nearsightedness, with or without astigmatism, and have maintained a stable prescription for at least one year. If you are seeking a solution to decrease or eliminate the cost and frustration of traditional contacts or glasses, EVO may be your answer. Contact us to discuss if EVO ICL is right for you.
Contact your eye doctor to discuss if EVO ICL is right for you.
The EVO Visian ICL lens is intended to correct/reduce nearsightedness between -3.0 D up to -20.0 D and treat astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO Visian ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses.
To determine if you are an appropriate candidate for EVO Visian ICL surgery, you should have a complete eye examination and talk with your eye care professional about potential benefits, risks, complications, and recovery time. Complications, although rare, may include need for additional surgical procedures, infection, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts.
You should NOT have EVO Visian ICL surgery if 1) your eye shape is not appropriate; 2) you do not meet the minimum endothelial cell density for your age; 3) you have moderate to severe glaucoma; 4) your vision is not stable; or 5) you are pregnant or nursing.
For additional important safety information, please visit EVOICL.com.
1Sanders D, Vukich J. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006
2Igarashi A, Kamiya K, Shimizu K, Komatsu M. Visual Performance after implantable Collamer lens implantation and wavefront-guided laser in situ keratomileusis for high myopia. Am J Opthalmol. 2009
3Parkhurst G, Psolka M, Kezirian G. Phakic intraocular lens implantation in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481
4Gimbel H, et al. Management of myopic astigmatism with phakic intraocular lens implantation. Journal of Cataract & Refractive Surgery, Volume 28, Issue 5, 883 – 886.
5Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017 Jul 3;11:1253-1263.
6Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016 Jun 29;10:1209-15.
7Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017 Jul 3;11:1253-1263.
Read Article and View Video